
Opinion|Videos|January 24, 2025
Key Strategies for Preventing CRS and ICANS
Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell lymphomas.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What are your key strategies for preventing CRS and ICANS in patients receiving bispecific therapies for B-cell lymphomas?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
4
Combination Therapy Proves More Effective in NSCLC Compared With Chemotherapy
5